Since PSA was considered a marker for prostate cancer screening by the US Food and Drug Administration in 19944, US health services had a dedicated prostate cancer screening until the year 2008, when prostate cancer screening with PSA reached a controversial status. This evidence concerns the gene KLK3 and prostate cancer.